Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 30.0% in December

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 185,292 shares, a decrease of 30.0% from the December 15th total of 264,718 shares. Approximately 7.0% of the shares of the company are sold short. Based on an average trading volume of 62,248 shares, the short-interest ratio is presently 3.0 days. Based on an average trading volume of 62,248 shares, the short-interest ratio is presently 3.0 days. Approximately 7.0% of the shares of the company are sold short.

Alzamend Neuro Trading Up 4.4%

Shares of ALZN stock opened at $2.35 on Monday. The stock has a 50 day simple moving average of $2.16 and a 200-day simple moving average of $2.41. The company has a market cap of $8.93 million, a price-to-earnings ratio of -0.71 and a beta of -0.25. Alzamend Neuro has a 12-month low of $1.69 and a 12-month high of $11.02.

Alzamend Neuro (NASDAQ:ALZN) last announced its quarterly earnings data on Tuesday, December 9th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.53. On average, equities analysts forecast that Alzamend Neuro will post -1.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Ascendiant Capital Markets lowered their target price on Alzamend Neuro from $42.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Alzamend Neuro in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $28.00.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.